Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegylated Liposomal Doxorubicin vs Epirubicin in Early Breast Cancer
NCT01210768Phase 2Unknown
- Sponsor
- TTY Biopharm Company Limited
- Start
- Jun 2010
- Primary completion
- Oct 2022
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
A Phase 2 trial of pegylated liposomal doxorubicin in breast cancer, sponsored by TTY Biopharm Company Limited. Status: unknown.
02
Drugs
pegylated liposomal doxorubicin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01210768.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01210768.